Together we will beat cancer

Donate now

Immunotherapy

Showing 12 out of 200 results
A magnified image of squamous cell carcinoma, the most common type of cervical cancer

The immunotherapy pembrolizumab may help some people with incurable cervical cancer live longer. It's now an approved treatment for them in England and Scotland. The immunotherapy pembrolizumab may help some people with incurable cervical cancer live longer. It's now an approved treatment for them in England and Scotland.

by Tim Gunn | News | 16 May 2023

16 May 2023

A scientist handling patient samples at an experimental cancer medicine centre.

We're helping treble funding for paediatric Experimental Cancer Medicine Centres, paving the way to more effective and less toxic treatments for children and young people. We're helping treble funding for paediatric Experimental Cancer Medicine Centres, paving the way to more effective and less toxic treatments for children and young people.

by Tim Gunn | In depth | 3 April 2023

3 April 2023

Vaccine vial and needle
  • Science & Technology
  • Health & Medicine

Cancer vaccines – where are we?

Cancer vaccine development has had many challenges. But with recent breakthroughs and new partnerships, could we be closer than ever? Cancer vaccine development has had many challenges. But with recent breakthroughs and new partnerships, could we be closer than ever?

by Sophie Wedekind | In depth | 24 February 2023

24 February 2023

Breast cancer cell seen through a scanning electron microscope

The "potentially life-saving" immunotherapy drug pembrolizumab is now recommended for some people with early triple negative breast cancer in England and Wales. The "potentially life-saving" immunotherapy drug pembrolizumab is now recommended for some people with early triple negative breast cancer in England and Wales.

by Tim Gunn | News | 14 November 2022

14 November 2022

T cell

Researchers in Southampton have found a way to improve the effectiveness of immunotherapy in cancers that are resistant by repurposing existing drugs Researchers in Southampton have found a way to improve the effectiveness of immunotherapy in cancers that are resistant by repurposing existing drugs

by Jacob Smith | Analysis | 11 November 2022

11 November 2022

Forty years ago, hints of a new component of the immune system caused a stir. Here, we chart the story of gamma delta T cells from discovery to clinical trials... Forty years ago, hints of a new component of the immune system caused a stir. Here, we chart the story of gamma delta T cells from discovery to clinical trials...

by Cancer Research UK | In depth | 18 March 2022

18 March 2022

3 new cancer treatments have now been approved by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland, including 2 breast cancer treatments and 1 for lung cancer. 3 new cancer treatments have now been approved by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland, including 2 breast cancer treatments and 1 for lung cancer.

by Harry Jenkins | News | 19 January 2022

19 January 2022

Non small cell lung cancer cells stained in pleural effusion sample.

A new treatment for some people with a type of non small cell lung cancer (NSCLC) will now be routinely available on the NHS in England, following its approval by the National Institute of Health and Care Excellence (NICE). A new treatment for some people with a type of non small cell lung cancer (NSCLC) will now be routinely available on the NHS in England, following its approval by the National Institute of Health and Care Excellence (NICE).

by Harry Jenkins | News | 12 January 2022

12 January 2022

Melanoma cell. Credit: Dr Erik Sahai

The National Institute for Health and Care Excellence has recommended the use of the immunotherapy drug pembrolizumab (Keytruda) for some adults in England with a type of advanced melanoma skin cancer. The National Institute for Health and Care Excellence has recommended the use of the immunotherapy drug pembrolizumab (Keytruda) for some adults in England with a type of advanced melanoma skin cancer.

by Harry Jenkins | News | 21 December 2021

21 December 2021

Lung cancer cells

Three new cancer drugs have been given the go-ahead by the Scottish Medicines Consortium (SMC) for routine use in Scotland, two for non small cell lung cancer and one for Hodgkin lymphoma, but a fourth has been rejected. Three new cancer drugs have been given the go-ahead by the Scottish Medicines Consortium (SMC) for routine use in Scotland, two for non small cell lung cancer and one for Hodgkin lymphoma, but a fourth has been rejected.

by Harry Jenkins | News | 11 November 2021

11 November 2021